{"name":"Robin, Alan L., M.D.","slug":"robin-alan-l-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"travoprost, latanoprost, or bimatoprost","genericName":"travoprost, latanoprost, or bimatoprost","slug":"travoprost-latanoprost-or-bimatoprost","indication":"Open-angle glaucoma","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Additional ocular hypotensive medication","genericName":"Additional ocular hypotensive medication","slug":"additional-ocular-hypotensive-medication","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"travoprost, latanoprost, or bimatoprost","genericName":"travoprost, latanoprost, or bimatoprost","slug":"travoprost-latanoprost-or-bimatoprost","phase":"marketed","mechanism":"These prostaglandin F (FP) receptor agonists increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Additional ocular hypotensive medication","genericName":"Additional ocular hypotensive medication","slug":"additional-ocular-hypotensive-medication","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBKMDAxclpZUlBMLVlETmFVcll4M0JLRHJ5eVFHMjJDN1p0RE4tOWJzZkpsN3hRN3ZaOFA1eFBmaGVZbzh1RTYzdGlrOW05TGVRbmVXLTU2SVVMdkU0Rm9LcFkyZlg0dlIt?oc=5","date":"2025-07-15","type":"pipeline","source":"EyeWorld","summary":"Sustainability in glaucoma - EyeWorld","headline":"Sustainability in glaucoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1Ca2ZHS3lvOFAzcTZwV1RVWDlqdU5TNVdWclQtM3A5bkFJVW1DOGNQYVhKdUIwck9VVkVFeFpRYWVNZEh0cTRjOWRoVkRTeUpPMHo4RTJXQXhhR0NIcVRCMXFtRF9VOUtXMVk1V2RtU0NoOU0?oc=5","date":"2025-04-14","type":"pipeline","source":"Psychiatry Online","summary":"New Trends in Peptide Therapies: Perspectives and Implications for Clinical Neurosciences - Psychiatry Online","headline":"New Trends in Peptide Therapies: Perspectives and Implications for Clinical Neurosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWTJSV3QyNG1JUjJBQ09WUllmNzZWbF9NUzFQVnlINDN5THlsNEdUalZoN0czbVI0OXgzdnpIVUNRT1JlaUtoZFQtTzczc2JDNGswQVNGWnRRX1k5S2JlVjF1UUJKNDhtRDVkRVpXcVdjYldBSC1BaFJLb3pLZnlpTkhYa2NoYkl0T25GSzI3RDBJbHJU?oc=5","date":"2024-12-09","type":"pipeline","source":"Frontiers","summary":"The fruit fly Drosophila melanogaster as a screening model for antiseizure medications - Frontiers","headline":"The fruit fly Drosophila melanogaster as a screening model for antiseizure medications","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPam1rRC05dkRGVTE3OGNOZWx3bTBSV2NZTDl3ZXh0ekNtNF8wU3VvM1BNS2VYMThIYVM5SmpMaFpOTm4xWXVGVGFLcFB5REZLVzhDN1RvTlZNcXlhN0U1R3FBajJkYW5pQnV5dHlhd0dUWVAxRlgyZVh5czNsWkZlSGttdjhwSzFMTlE?oc=5","date":"2017-03-19","type":"pipeline","source":"The New York Times","summary":"Robin Levine, Jesse Dymond (Published 2017) - The New York Times","headline":"Robin Levine, Jesse Dymond (Published 2017)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE40dVlheUt6emxBRUtQSjBMQU1NbWFzN0FDaVVoLVFabDNzZW9uS2JrV2lWMG5LZWl2NUV2QWFvem0xTjRDYS10RUpWM3FBZG5IdWdQQmxjNW9BVWxGR0V2eTZtODd2YjBEc0QxUmJCc1Q2b1U?oc=5","date":"2016-04-19","type":"pipeline","source":"Psychiatry Online","summary":"Clinical Positron Emission Tomography (PET) Neuroimaging: Advantages and Limitations as a Diagnostic Tool - Psychiatry Online","headline":"Clinical Positron Emission Tomography (PET) Neuroimaging: Advantages and Limitations as a Diagnostic Tool","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}